These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 24423412)

  • 1. Cisplatin-induced epigenetic activation of miR-34a sensitizes bladder cancer cells to chemotherapy.
    Li H; Yu G; Shi R; Lang B; Chen X; Xia D; Xiao H; Guo X; Guan W; Ye Z; Xiao W; Xu H
    Mol Cancer; 2014 Jan; 13():8. PubMed ID: 24423412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-150 modulates cisplatin chemosensitivity and invasiveness of muscle-invasive bladder cancer cells via targeting PDCD4 in vitro.
    Lei Y; Hu X; Li B; Peng M; Tong S; Zu X; Wang Z; Qi L; Chen M
    Med Sci Monit; 2014 Oct; 20():1850-7. PubMed ID: 25287716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status.
    Vinall RL; Ripoll AZ; Wang S; Pan CX; deVere White RW
    Int J Cancer; 2012 Jun; 130(11):2526-38. PubMed ID: 21702042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC).
    Bunch B; Krishnan N; Greenspan RD; Ramakrishnan S; Attwood K; Yan L; Qi Q; Wang D; Morrison C; Omilian A; Bshara W; Pili R; Trump DL; Johnson C; Woloszynska A
    Cell Cycle; 2019 Sep; 18(17):2055-2066. PubMed ID: 31318640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer.
    Xylinas E; Hassler MR; Zhuang D; Krzywinski M; Erdem Z; Robinson BD; Elemento O; Clozel T; Shariat SF
    Biomolecules; 2016 Sep; 6(3):. PubMed ID: 27598218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIF-1α-dependent miR-424 induction confers cisplatin resistance on bladder cancer cells through down-regulation of pro-apoptotic UNC5B and SIRT4.
    Yu M; Ozaki T; Sun D; Xing H; Wei B; An J; Yang J; Gao Y; Liu S; Kong C; Zhu Y
    J Exp Clin Cancer Res; 2020 Jun; 39(1):108. PubMed ID: 32522234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miRNA-34a suppresses cell proliferation and metastasis by targeting CD44 in human renal carcinoma cells.
    Yu G; Li H; Wang J; Gumireddy K; Li A; Yao W; Tang K; Xiao W; Hu J; Xiao H; Lang B; Ye Z; Huang Q; Xu H
    J Urol; 2014 Oct; 192(4):1229-37. PubMed ID: 24866595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-34a Attenuates Metastasis and Chemoresistance of Bladder Cancer Cells by Targeting the TCF1/LEF1 Axis.
    Liu X; Liu X; Wu Y; Fang Z; Wu Q; Wu C; Hao Y; Yang X; Zhao J; Li J; Wang Q; Yang Z; Xu J; Hu X; Tan M; Li L
    Cell Physiol Biochem; 2018; 48(1):87-98. PubMed ID: 30001529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcribed ultraconserved region Uc.63+ promotes resistance to cisplatin through regulation of androgen receptor signaling in bladder cancer.
    Sekino Y; Sakamoto N; Ishikawa A; Honma R; Shigematsu Y; Hayashi T; Sentani K; Oue N; Teishima J; Matsubara A; Yasui W
    Oncol Rep; 2019 May; 41(5):3111-3118. PubMed ID: 30864720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maspin enhances cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and correlates with prognosis of muscle-invasive bladder cancer patients receiving cisplatin based neoadjuvant chemotherapy.
    Chen J; Wang L; Tang Y; Gong G; Liu L; Chen M; Chen Z; Cui Y; Li C; Cheng X; Qi L; Zu X
    J Exp Clin Cancer Res; 2016 Jan; 35():2. PubMed ID: 26733306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer.
    Okamura S; Yoshino H; Kuroshima K; Tsuruda M; Osako Y; Sakaguchi T; Yonemori M; Yamada Y; Tatarano S; Nakagawa M; Enokida H
    BMC Cancer; 2021 Jan; 21(1):48. PubMed ID: 33430801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.
    Seiler R; Oo HZ; Tortora D; Clausen TM; Wang CK; Kumar G; Pereira MA; Ørum-Madsen MS; Agerbæk MØ; Gustavsson T; Nordmaj MA; Rich JR; Lallous N; Fazli L; Lee SS; Douglas J; Todenhöfer T; Esfandnia S; Battsogt D; Babcook JS; Al-Nakouzi N; Crabb SJ; Moskalev I; Kiss B; Davicioni E; Thalmann GN; Rennie PS; Black PC; Salanti A; Daugaard M
    Eur Urol; 2017 Jul; 72(1):142-150. PubMed ID: 28408175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
    Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
    Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNMT3B silencing suppresses migration and invasion by epigenetically promoting miR-34a in bladder cancer.
    Xu K; Chen B; Li B; Li C; Zhang Y; Jiang N; Lang B
    Aging (Albany NY); 2020 Nov; 12(23):23668-23683. PubMed ID: 33221743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA methyltransferase mediates the hypermethylation of the microRNA 34a promoter and enhances the resistance of patient-derived pancreatic cancer cells to molecular targeting agents.
    Ma Y; Chai N; Jiang Q; Chang Z; Chai Y; Li X; Sun H; Hou J; Linghu E
    Pharmacol Res; 2020 Oct; 160():105071. PubMed ID: 32659427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1.
    Xu S; Fu GB; Tao Z; OuYang J; Kong F; Jiang BH; Wan X; Chen K
    Oncotarget; 2015 Sep; 6(28):26457-71. PubMed ID: 26238185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The miR-34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene.
    Pu Y; Zhao F; Li Y; Cui M; Wang H; Meng X; Cai S
    BMC Cancer; 2017 Jan; 17(1):45. PubMed ID: 28073349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circular RNA Cdr1as sensitizes bladder cancer to cisplatin by upregulating APAF1 expression through miR-1270 inhibition.
    Yuan W; Zhou R; Wang J; Han J; Yang X; Yu H; Lu H; Zhang X; Li P; Tao J; Wei J; Lu Q; Yang H; Gu M
    Mol Oncol; 2019 Jul; 13(7):1559-1576. PubMed ID: 31131537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a.
    Cheng C; Qin Y; Zhi Q; Wang J; Qin C
    Int J Biol Macromol; 2018 Feb; 107(Pt B):2620-2629. PubMed ID: 29080815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of microRNAs in urinary bladder samples obtained from dogs with grossly normal bladders, inflammatory bladder disease, or transitional cell carcinoma.
    Vinall RL; Kent MS; deVere White RW
    Am J Vet Res; 2012 Oct; 73(10):1626-33. PubMed ID: 23013190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.